VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.15 USD
+0.15 (5.00%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $3.13 -0.02 (-0.63%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for VistaGen Therapeutics, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 1 | 1 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 1 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 34 | 59 | 49 | 19 | 21 |
Income After Depreciation & Amortization | -33 | -59 | -48 | -18 | -21 |
Non-Operating Income | 4 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -29 | -59 | -48 | -18 | -21 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -59 | -48 | -18 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -59 | -48 | -18 | -21 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -33 | -59 | -48 | -18 | -21 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -33 | -59 | -48 | -18 | -21 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 19.36 | 6.96 | 6.59 | 2.87 | 1.46 |
Diluted EPS Before Non-Recurring Items | -1.52 | -8.51 | -7.51 | -14.72 | -15.02 |
Diluted Net EPS (GAAP) | -1.52 | -8.51 | -7.51 | -14.71 | -15.02 |
Fiscal Year end for VistaGen Therapeutics, Inc falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.08 | 0.20 | 0.41 | 0.28 | 0.18 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.08 | 0.20 | 0.41 | 0.28 | 0.18 |
SG&A, R&D, and Dept/Amort Expenses | 12.22 | 11.56 | 8.30 | 7.06 | 7.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | -12.14 | -11.36 | -7.89 | -6.78 | -7.00 |
Non-Operating Income | 1.40 | 1.53 | 1.53 | 0.19 | 0.10 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -10.73 | -9.52 | -6.35 | -6.59 | -6.90 |
Income Taxes | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.73 | -9.51 | -6.35 | -6.59 | -6.90 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.73 | -9.52 | -6.35 | -6.59 | -6.90 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 30.60 | 38.41 | 29.39 | 10.04 | 7.38 |
Diluted EPS Before Non-Recurring Items | -0.35 | -0.25 | -0.22 | -0.66 | -0.94 |
Diluted Net EPS (GAAP) | -0.35 | 0.30 | -0.22 | -0.66 | -0.94 |